MeCure Industries Plc had its long-term issuer rating affirmed at BBB(NG) and short-term rating at A3(NG) by GCR Ratings, with the outlook revised to stable from positive.
The Lagos-based pharmaceutical company closed the first half of 2026 with improved earnings and market penetration, the firm said in a statement.
The rating agency cited MeCure’s stronger competitive position, sound earnings performance and ongoing expansion.
GCR pointed to product innovation and wider distribution as key drivers, noting the company’s portfolio of more than 140 formulations across five therapeutic classes.
Its extensive distribution network and relationships with suppliers and technical partners also supported the affirmation, the statement said.
MeCure closed H1 2026 on a strong note with two additional milestones: it secured Halal certification and launched two new products, expanding access to Muslim consumers and adding to its drug portfolio.
The moves come as Nigeria’s pharmaceutical firms invest in local manufacturing and import
This post was originally published on this site.
